efficacy of kasmitad gel in the management of recurrent minor aphthous ulceration

ABSTRACT

To evaluate the efficacy and safety of Kasmitad [trade mark] gel for the treatment of recurrent minor aphtous ulceration, particularly when applied at the onset of prodromal symptoms. Self-controlled before - after study conducted during a 26-month period [October 2007 - September 2009]. Outpatient clinic at the School of Stomatology, Tongji University, Shanghai, China. Seventy patients with recurrent minor aphthous ulceration were randomized into the prodromal or ulceration group. Four parameters [pain score, ulcer incidence, size, duration] were recorded before and after treatment. Incidence of ulcer occurrence after treatment at different stages; changes in ulcer size, duration and pain score. Only 75.8% of subjects in the prodromal group developed an ulcer. Compared with no treatment, the maximum pain score, ulcer size, and ulcer duration were clearly reduced for subjects in both groups [p <0.01]. The two groups showed significant differences in the reduction of ulcer size and duration [p < 0.01], but no significant difference in pain scores [p= 0.236]. In the treatment of recurrent aphthous ulceration, the use of Kasmitad [trade mark] gel at the onset of prodromal symptoms can prevent progression to ulcer development and significantly reduce symptoms if ulcers do develop